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trix of proteoglycans and collagen mineralized by
the deposition of calcium hydroxyapatite1. Bone
remodeling results from the balance between os-
teoblast and osteoclast activity, through four pha -
ses: activation, resorption, reversal and formation.
This includes removal of trenches or tunnels of
bone from the surfaces of trabecular and cortical
bone, respectively, by osteoclasts, while osteoblasts
subsequently fill in these trenches by laying down
new bone matrix2.
Formation matches resorption during normal
bone remodeling. This remodeling becomes dis-
turbed in a variety of pathologic conditions that af-
fect the skeleton (osteoporosis, glucocorticoid-in -
du ced bone loss, multiple myeloma, and rheuma-
toid arthritis)2,3. Discovery of the receptor activator
of nuclear factor-kB (RANK)/RANK ligand (RANKL)/
/osteoprotegerin (OPG) signaling pathway as a 
major regulatory system for osteoclast formation
and action, showed the major role of the tumor ne -
crosis factor (TNF) superfamily in bone meta -
bolism1,5. 
Studies also revealed new functions of this triad
in other pathologies and tissues, and suggest that
in response to mechanical forces osteocytes regu-
late the osteoclasts recruitment to sites of bone re-
sorption, by inducing the RANKL expression by os-
teoblastic cells in the local micro-environment2-4.
Emerging treatments have been explored accord-
ing to new molecules and mechanisms discoveries. 
Osteoblasts differentiation and proliferation de-
pends on Wingless (Wnt)/β-catenin pathway and
mutations on some of their proteins lead to bone di -
seases (eg. loss-of-function mutation in the Wnt 
co-receptor low-density lipoprotein receptor-rela-
ted protein 5 (LRP5) is associated with osteoporo-
sis)6,7.
In this article, we will review RANK/RANKL/OPG
triad, its role in the bone, and recent concepts. 
RANK, RANKL and OPG signaling pathway
Ostoblasts are mononuclear cells responsible for
Abstract
The discovery of the receptor activator of nuclear
factor-kB (RANK)/RANK Ligand (RANKL)/osteo-
protegerin (OPG) pathway contributed to the un-
derstanding of how bone formation and resorption
were processed and regulated. RANKL and OPG are
members of the tumor necrosis factor (TNF) and
TNF receptor (TNFr) superfamilies, respectively,
and binding to receptor activator of NF-kB (RANK)
not only regulate osteoclast formation, activation
and survival in normal bone modeling and remode -
ling, but also in several other pathologic conditions
characterized by increased bone turnover. There is
accumulating evidence of the potential role of OPG
and RANKL in other tissues.
Looking beyond the RANK/RANKL/OPG axis,
Wingless (Wnt) pathway emerged as the osteoblast
differentiation way, and also as a bone mass regulator. 
Researchers have been discovering new
molecules and cytokines interactions. Altogether,
data suggest that RANK/RANKL/OPG system could
be targeted as a new treatment strategy in bone
conditions. FREEDOM is the more recently pub-
lished clinical trial about a RANKL-specific recom-
binant fully human monoclonal antibody (deno-
sumab). OPG is also a potential innovative thera-
peutic option to be investigated. 
Keywords: RANK; RANKL; Osteoprotegerin; Os-
teoclast; Bone Formation.
Introduction
Bone is a connective tissue made up of specific
cells, osteoblasts (bone-forming), osteocytes (os-
teoblasts entrapped within lacunae) and osteo-
clasts (bone-reabsorbing), and an extracellular ma-
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the deposition of bone matrix and for osteoclasts
regulation. They originate from mesenchymal
stem cells (MSC) by the action of transcription fac-
tors like core binding factor α1 (Cbfa-1) also known
as Runx2, osterix (Osx), activating transcription
factor 4 (ATF4), and bone morphogenic proteins
(BMP) as BMP46. Osteoclasts are derived from
mononuclear precursors in the myeloid lineage of
hematopoietic cells that also originate macro pha -
ges2. Macrophage-colony stimulating factor (M-
-CSF) expression by osteoblastic stromal cells is
required for progenitor cells to differentiate into
osteo clasts, but is unable to complete this process
by its own. In a 1997 publication OPG was identi-
fied, and its gene encoded a member of the TNF re-
ceptor family. In a 1998 publication RANKL was re-
ported as a new member of the TNF family that
could bind to OPG and RANK8. RANK/RANKL/
/OPG are closely linked with each other. 
RANKL is synthesized in membranous or solu-
ble form by the osteoblastic lineage cells, the 
immune cells, and some cancer cells. This factor
links to the osteoclasts surface receptor, RANK, 
and stimulates bone resorption through osteo-
clastogenesis and the activation of multinuclea-
ted mature osteoclasts. OPG that is secreted by 
osteoblasts as a decoy receptor for RANKL, pre-
vents RANKL from binding to RANK and bone re-
sorption1-6.
In the immune system RANKL in activated T
cells binds to RANK expressed by the dendritic
cells, regu lating the function and survival of those
cells. OPG is produced by B-lymphocytes and den-
dritic cells, maintaining an equilibrium in this sys-
tem1. 
OPG
OPG belongs to the TNF receptor superfamily 
(TNFRS), preventing the biological effects of RANKL.
Also known as TNFRS member 11B (TNFRS11B),
osteoclastogenesis inhibitory factor (OCIF) and
tropine reductase 1 (TR1), is highly expressed as a
soluble protein, closely related to CD40 and able
to bind to CD40 ligand (CD40L). Is produced in the
adult lung, heart, kidney, liver, thymus, lymph
nodes, bone marrow, osteoblasts, vascular smooth
muscle cells, B-lymphocytes, and articular chon-
drocytes1-3,6. Over expression of OPG in the mice re-
sulted in osteopetrosis and its deficiency deter-
mined osteoporosis6. The osteoprotective role of
OPG is supported by the report of homozygous
deletions of 100 kilobases of OPG in juvenile Paget’s
disease, and the inactivating deletion in exon 3 of
OPG in idiopathic hyperphosphatasia3.
When RANKL expression is up-regulated OPG
expression is down-regulated or not induced to the
same degree as RANKL, and the RANKL/OPG ra-
tio favors osteoclastogenesis2. OPG expression in
osteoblasts is increased by vitamin D3, interleukin
(IL)-1α, IL-1β, TNFα, TNFβ, BMP2, transforming
growth factor β (TGFβ) and 17 -estradiol and Wnt
signaling pathway. Its expression is decreased by
prostaglandin E2 (PGE2), parathyroid hormone
(PTH), glucocorticoids and insulin-like growth fac-
tor-1 (IGF-1) (Figure 1)4.
Furthermore, the RANKL/OPG ratio expressed
by pre-osteoblasts cells is higher than in mature 
osteoblasts, favoring osteoclasts maturation and
action. Jagged1/Notch1 signaling negatively regu-
lates osteoclast formation directly and indirectly 
by changing RANKL/OPG ratio in stromal cells. 
So, bone mass is regulated by osteoblasts through
three signaling pathways: RANKL/RANK, Wnt/
/β-catenin and Jagged1/Notch12. Jagged 1 is a 180
kDa type I transmembrane glycoprotein with 
an extracellular DSL (delta, serrate, lag-2 consen-
sus sequence) domain that is necessary for bin-
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Fi­gu­re­1.­Regulatory mechanisms of bone remodeling:
role of RANK, RANKL and OPG in osteoclast activation.
OPG expression in osteoblasts is increased by vitamin 
D3, interleukin (IL) -1α, IL-1β, TNFα, TNFβ, BMP2, 
transforming growth factor β (TGFβ) and 17β-estradiol,
and Wnt signaling pathway. Its expression is decreased by
prostaglandin E2 (PGE2), parathyroid hormone (PTH), 
glucocorticoids and insulin-like growth factor-1 (IGF-1). 
From: Vega D, Maalouf NM, Sakhaee K. The role of 
receptor activator of nuclear factor-kB (RANK)/RANK
ligand/Osteoprotegerin: clinical implications. The journal 
of clinical endocrinology and metabolism. 2007; 92:
4514-4521.
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ding to Notch receptors. Jagged-Notch signaling
specifies cell fate, modulates cell proliferation and
differentiation, especially during hematopoiesis,
myoge nesis, neurogenesis and development of the
vasculature. Direct cell-cell interactions are
thought to be necessary for functional Notch sig-
naling2,6.
In mammals there are four Notch receptors
(Notch 1-4). The canonical Notch signaling in
skeletal biology is evolving while the non-canoni-
cal is poorly understood9. Suppression of Notch
signaling by a selective g-secretase inhibitor or
Notch2 short hairpin RNA suppressed RANKL-in-
duced osteoclastogenesis. Induction of Notch sig-
naling by Jagged1 or by ectopic expression of in-
tracellular Notch2 enhanced nuclear factor of acti -
vated T cells 1 (NFATc1) promoter activity leading
to the increase of osteoclastogenesis10. In a patho-
logical context, aberration of Notch signaling is as-
sociated with osteosarcoma9,10.
RANKL
RANKL belongs to the TNF superfamily, is ex-
pressed in bone, lung, bone marrow and lymphoid
tissues, and exists as 3 isoforms: RANKL 1, 2 and 3.
These three isoforms of this type II homotrimeric
transmembrane protein can differentially regulate
osteoclastogenesis and exists as a soluble and a
membranous form. Soluble form has low capacity
to generate osteoclasts11. Typically is expressed in
a membrane-bound form in osteoblasts and acti-
vated T cells, and after a proteolytic cleavage by
matrix metalloproteases (MMP3 or 7) or a disinte-
grin and metallopeptidase (ADAM) is secreted. Its
expression by synovial cells and activated T cells 
in patients with rheumatoid arthritis contributes,
with TNF, to joint destruction1,2,8. RANKL sti-
mulates the release of immature osteoclasts 
progenitors into the circulation. Analysis of RAN-
KL promoter revealed the presence of binding 
sites for vitamin D and glucocorticoids (stimula-
tors)6. Clinical studies in mice showed RANKL ex-
pression in mammary epithelial cells during preg-
nancy and its effect in lactational hyperplasia of
mammary epithelial cells and milk production.
RANKL is also expressed by some malignant tu-
mors cells, thus regulating tumor cell proliferation
and probably migration1,2. Recently, the first report
of a mutation in the RANKL gene was described 
in Canada. The affected individuals had osteope -
trosis, without obvious defect in immunologic 
system2.
MicroRNAs (miRs) are small non-coding RNAs
that function in the spatiotemporal regulation of
protein translation in animal cells. MiR-21 was
identified as a miR expression signature of RANKL-
-induced osteoclastogenesis that down-regulates
programmed cell death 4 (PDCD4) protein level,
and RANKL-induced c-Fos up-regulates miR-21
gene expression12.
RANK
RANK belongs to the TNFR superfamily, is synthe-
sized as a type I homotrimeric transmembrane
protein, and is expressed by different tissues such
as skeletal muscle, thymus, liver, colon, mamma-
ry glands, prostate, pancreas, and cells of the
monocyte/macrophage lineage (precursors and
mature osteoclasts, B and T cells, dendritic cells, fi-
broblasts, and articular chondrocytes). RANKL
produced by osteoblasts binds to RANK in the sur-
face of osteoclasts, recruits the tumor necrosis fac-
tor receptor associated factor (TRAF) 2,5 and 6 that
bind to RANK cytoplasmic domain (only TRAF6
seems to be essential in osteoclasts), leading to 
NF-kB activation and translocation to the nucleus.
NF-kB increases c-Fos expression and c-Fos inte -
racts with NFATc1 to trigger the osteoclastogenic
genes transcription (Figure 2). At least seven signa -
ling pathways are activated by RANK-mediated
protein kinase signaling: four mediate osteoclas-
togenesis (inhibitor of NF-kB kinase/NF-kB, c-Jun
amino-terminal kinase/activator protein-1, c-myc,
and calcineurin/NFATc1) and three mediate osteo -
clast activation [Rous sarcoma oncogene (src) and
mi togen-activated protein kinase kinase 6
(MKK6)/p38/microphthalmia-associated trans -
cription factor (MITF)] and survival (src and ex-
tracellular signal-regulated kinase)1,2,6,8.
On the basis of mice studies, NFATc1 was des -
cribed as the master regulator of osteoclastogene-
sis (Figure 3). It is activated by a calcium-depen-
dent calcineurin dephosphorylation. However
some patients treated with cyclosporine A (NFATc1
inhibition) presented bone loss, what brought an-
other explanation: NFATc1 also positively regulates
expression of osterix, an essential transcription
factor in osteoblast function, and the result of this
net effect is reduced bone formation and osteo-
porosis3.
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OPG/RANKL complex
The OPG/RANKL ratio is considered to better re-
flect the bone remodeling environment signs. A
high ratio represents bone formation while a low
ratio favors bone resorptio1,4.
After OPG/RANKL complex formation, its in-
ternalization can be either through lipid rafts by
membranous syndecan-1 or by the clathrin coat
formation pathway. These two mechanisms con-
trol the bioavailability of extracellular OPG. In 
addition, glycosami noglycans (GAGs) such as
hepa rin, heparin sulfate, chondroitin sulfate and
dermatan sulfate binds OPG via the heparin bin -
ding domains and compete with OPG/RANKL in-
teraction, thus preventing OPG internalization
through membranous RANKL. This internalization
process is of particular importance for future
thera peutic involvement of OPG1.
The anti-resorptive effect of OPG can be ex-
plained by its properties of a decoy receptor and as
a modulator of RANKL half-life. As RANKL and
OPG controls each other bioavailability, the ba -
lance between RANKL and soluble OPG will be im-
portant for a curative application of OPG1.
RANK/RANKL/OPG pathway in rheumatological
conditions 
Bone diseases are related to increased bone re-
sorption, disturbed coupling between bone for-
mation and resorption, and bone destruction2.
GENETIC DISORDERS: familiar expansile osteolysis
[activating 18-bp tandem duplication in the gene
coding RANK (TNFRSF11A)]; familiar form of ear-
ly-onset Paget disease of bone (similar 27-bp dupli-
cation of the previous gene); expansile skeletal hy-
perphosphatasia (15-bp tandem duplication in
RANK); idiopathic hyperphosphatasia or juvenile
Paget disease [homozygous complete deletion of
OPG gene (TNFRSF11B)]5. Sabacchi et al13, repor -
ted mutations in the gene encoding RANKL in 6 pa-
tients with autossomal recessive osteopetrosis.
RHEUMATOID ARTHRITIS (RA):RANKL has been im-
plicated as an important mediator of bone ero-
sion14. Synovial T cells express RANKL and there is
an over expression of RANKL messenger RNA
(mRNA) and OPG in the RA patients synovium at
the site of bone resorption, which contributes to
osteoclast differentiation and activity14-16. OPG
binding to soluble RANKL can better prevent os-
teoclast activation in non erosive arthritis than in
RA17.  Elevated serum levels of soluble RANKL nor-
malize after anti-TNF therapy4,8,14.  Assmann et al,
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Fi­gu­re­2.­The essential signaling pathway for normal 
osteoclastogenesis. RANKL produced by osteoblasts binds
to RANK in the surface of osteoclasts, recruits the tumor
necrosis factor receptor associated factor (TRAF) 2,5 and
6 that bind to RANK cytoplasmic domain (only TRAF6
seems to be essential in osteoclasts), leading to NF-kB 
activation and translocation to the nucleus. NF-kB 
increases c-Fos expression and c-Fos interacts with FATc1
to trigger the osteoclastogenic genes transcription. 
From: Boyce BF, Xing L. Biology of RANK, RANKL, an 
osteoprotegerin. Arthritis research and therapy. 2007;9:1-7.
Fi­gu­re­3.­Signaling pathways involved osteoclastogenesis
in diseases states with the activation of NFATc1. On the
basis of mice studies, NFATc1 was described as the 
master regulator of osteoclastogenesis. From: Boyce BF,
Xing L. Functions of RANKL/RANK/OPG in bone 
modeling and remodeling. Archives of biochemistry and
biophysics. 2008; 473:139-146.
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studied genetic variations of this pathway in the
susceptibility to RA and showed the minor allele of
the RANK SNP rs35211496 might be protective
against RA18. Haynes et al, confirmed the hypo -
thesis that successful treatment with modifying
anti-rheumatic drugs (DMARDs) reduce RAN-
KL/OPG ratio, suppressing osteoclast formation in
the RA synovial tissue19,20.
SPONDYLOARTHROPATHIES (SPA): the pattern of
paraarticular bone tissue damage is different be-
tween different forms of peripheral arthritis. In SpA
there is limited degradation of the paraarticular
bone with new bone formation that can result in
ankylosis21. In human SpA are described osteo-
clastic foci in the subchondral bone marrow of hip
joints, which suggests a relation with cartilage-in-
duced inflammation (the osteoclasts number is
not increased at axial inflammation sites). The
RANK/RANKL/OPG pathway contribute to bone
erosions was demonstrated in RA, and also psoria -
tic arthritis (PsA), but only scarcely in peripheral
joint inflammation in SpA21. Vandooren et al22,
demonstrated that both RANKL (mostly by ca -
dherin 11-expressing synovial fibroblasts and CD3
T cells) and OPG were expressed in the inflamed
synovium; the presence of osteoclasts precursors
in the inflamed synovial tissue and that the factors
needed to local osteoclastogenesis are present in
the SpA synovium. There were no qualitative or
quantitative differences in the expression of RAN-
KL, OPG, and RANK between nonpsoriatic SpA,
psoriatic SpA and RA synovium with the same de-
gree of inflammation. They conclude that the rela -
tive protection against bone erosion in SpA cannot
be explained by differences of RANK/RANKL/OPG
synovial expression, and that these factors expres-
sion is disconnected from systemic and local in-
flammation22.
OSTEOPOROSIS: in human osteoblastic cell lines
have been shown a dose and time-dependent in-
crease in OPG mRNA in response to 17-estradiol,
which probably decreases the RANK-RANKL bind-
ing and osteoclastic bone resorption. Human bone
marrow cells from untreated early postmeno -
pausal women showed a greater expression of
RANKL compared to the estrogen-treated group4,8.
Ominsky et al, showed that ovariectomy in rats was
associated with high levels of serum RANKL and
osteoclast surface and reduced areal and volu-
metric BMD23. It was also showed that OPG re-
duced osteoclast surface and prevented ovaritec-
tomy-associated bone loss in the lumbar vertebrae,
distal femur and femur neck23. In the glucocorti-
coid-induced osteoporosis the RANK/RANKL/
/OPG role was described: glucocorticoids stimu-
late RANKL expression by osteoclasts and inhibit
OPG synthesis, favoring osteoclasts differentiation
and proliferation (increased RANKL/OPG ratio and
urinary and serum markers of bone resorption)4,8.
OSTEOARTHRITIS (OA): OPG and RANKL have
been found to be expressed and modulated in hu-
man OA subchondral bone, and by other articular
chondrocytes. The OPG/RANKL ratio in the syno -
vial fluid is greater in OA compared to RA. There are
two different phenotypes of subchondral bone os-
teoblasts, L-OA (low endogenous levels of PGE2)
and H-OA (high endogenous levels of PGE2). L-OA
presents low PGE2 level, low OPG/RANKL ratio,
high osteoclastogenesis and a decreased sub-
chondral bone thickness; while H-OA shows high
PGE2 level, high OPG/RANKL ratio, low osteoclas-
togenesis, and an increased subchondral bone
thickness1,24. A recent in vitro study with human 
L-OA subchondral bone osteoblasts showed that
the combination of glucosamine and chondroitin
sulfate modulated OPG/RANKL ratio, decreasing
bone resorption25. The addition of OPG or the inhi -
bition of RANKL would be beneficial on the sub-
chondral bone of the L-OA (resorptive phase), whi -
le in the H-OA patients the anti-resorptive agents
are less effective as the subchondral bone seems to
be in a formation phase1. Moreno-Rubio et al24,
sho wed that in patients with OA celecoxib de-
creased RANKL synthesis in the cartilage by in-
creasing the OPG:RANKL ratio; in vitro, PGE2 regu -
lated the expression and release of the mediators
of bone metabolism by articular chondrocytes.
POLYMIALGIA RHEUMATIC (PMR): Pusatelli et al26,
found no significant differences in circulating OPG
levels in PMR patients in the active phase of the di -
sease or the follow-up compared to normal con-
trols; the systemic RANKL (sRANKL) production is
increased, is not modulated by corticosteroid treat-
ment, and can be related to bone osteoporosis.
SYSTEMIC SCLEROSIS (SS): microvascular damage
is an early pathogenetic event in SS and RANK/
/RANKL/OPG system is involved in vascular biolo -
gy. Dovio et al27, showed that higher sRANKL levels
and sRANKL/OPG ratio in patients with SS are a
consequence of altered bone microenvironment,
and showed dissociation between the well esta -
blished activation/injury endothelial marker, so -
luble vascular cell adhesion molecule (sVAM), and
OPG, as another vascular damage marker.
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JUVENILE DERMATOMYOSITIS ( JDM): Rouster-
-Stevens et al28, documented that at the time of
diag nosis of JDM untreated patients have an eleva -
ted RANKL/OPG ratio compared to normal con-
trols, and this ratio is related to lower bone mine -
ral density (BMD)29,30.
RANK/RANKL/OPG pathway in 
non-rheumatologic conditions  
There is accumulating evidence of the potential
role of OPG and RANKL in other tissues (Figure 4)1. 
BONE TUMORS: osteoclastic activating factors are
produced by myeloma cells in response to IL-1, IL-
-6 and TNF-α. IL-7 may increase RANKL produc-
tion in T cells, and there is also an increased lyso-
somal degradation of OPG. Although serum OPG
levels correlated with World Health Organization
multiple myeloma performance status, it have not
be found to be associated with clinical stage or sur-
vival4,29.Myeloma cells release not only RANKL, but
also dickkopff-1 (DKK-1), which suppresses bone
formation, enhancing tumor growth. In metasta -
tic bone diseases, tumor cells increase RANKL:OPG
ratio directly and by T cells, osteoblast/stromal
cells and endothelial cells, together with PTH re-
lated peptide, increasing bone removal and tumor
growth8.
VASCULAR CALCIFICATION:  there are two main types
of vascular calcification, depending if the calcium
deposits are located in the intima (intimal calcifi-
cation, related to atherosclerotic plaques) or in the
medial layer (medial calcification, related to chro -
nic kidney disease). An imbalance in the RANK/
/RANKL/OPG system was suggested as responsi-
ble for the calcification process of atherosclerotic
plaques4. The identification of tissue-specific iso-
forms could increase the importance of sRANKL
and OPG in predicting calcified plaque rupture31,32.
However, direct evidence of a role of RANKL on
vascular calcification is missing33. Panizo et al33,
showed that RANKL is able to induce vascular
smooth muscle cells (VSMCs) calcification in vit-
ro by binding to RANK; RANK activation will in-
crease BMP4 expression by stimulating alternative
NF-kB pathway. The inhibition of RANKL maybe is
a possible target to treat vascular calcification33,34.
INFLAMMATORY BOWEL DISEASE (IBD): Moschen et
al35, demonstrated that IBD is related to alterations
in the RANKL/OPG system, and elevated RANKL/
/OPG ratio is associated to bone loss.
DIABETES MELLITUS (DM): Secchiero et al36, sho -
wed that OPG but not the RANKL is significantly in-
creased in type 2 DM patients compared to con-
trols; serum OPG increases early after DM induc-
tion in mice, and showed a positive correlation
with blood glucose levels and inverse correlation
with  free RANKL levels. Thus, increased OPG pro-
duction represents an early event in DM and pos-
sibly is related to endothelial cell dysfunction.
CHRONIC ALCOHOLIC LIVER DISEASE: OPG is raised in
alcoholics, especially in cirrhotics without relation
with decreased BMD. Raised TNF and IL-6 levels
were related with increased OPG levels, which sup-
port the protective effect of OPG in bone loss37.
THYROID TUMORS: the role of RANK/RANKL/OPG
in thyroid pathophysiology remains unclear. Hey-
mann et al38, showed that RANK/RANKL/OPG is
expressed in the pathological thyroid gland by fol-
licular cells, by malignant parafollicular cells, and
in metastatic lymph node microenvironment.
Thus this system might have a role in the patho-
genesis of these tumors.
CHRONIC RENAL FAILURE: Fahrleitner-Pammer et
al39, demonstrated that RANK/RANKL/OPG sys-
tem is associated with BMD in predialysis chronic
renal failure. Serum OPG concentrations are lo wer
in patients with adynamic bone disease, in contrast
to those with increased bone turnover due to se -
condary hyperparathyroidism. It is possible that
increased serum OPG in chronic kidney disease
patients is an adaptative mechanism to attenuate
PTH-induced bone loss4.
BREAST AND PROSTATE CANCER: OPG production by
breast cancer cells is a possible survival mecha-
nism of the tumoral cells, because OPG inhibits
TNF-related apoptosis-inducing ligand (TRAIL).
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Fi­gu­re­4.­The role of the RANKL/RANK system in bone
and other tissues. From: Boyce BF, Xing L. Biology of
RANK, RANKL, an osteoprotegerin. Arthritis research and
therapy. 2007;9:1-7.
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OPG is also a potential indicator for the diagnosis
and early progression of prostate cancer (elevated
levels)4.
Wnt signaling pathway: interaction with
RANK/RANKL/OPG
The Wnt proteins are a family of secreted growth
factors found in all animal species that bind to cell-
-surface receptors and regulate cellular activities
like cell fate, determination, proliferation, migra-
tion, polarity, and gene expression6. Genes enco -
ding for Wnt proteins are highly conserved. At least
four signaling pathways are described: Wnt/
/β-catenin; planar cell polarity; Wnt/Ca2+; and pro-
tein kinase A. 
The main biologic functions of the Wnt pathway
in bone metabolism are: mesenchymal cell diffe -
rentiation, implications in multiple myeloma and
metastatic bone disease, bone mass regulation and
bone response to mechanical loading.
The Wnt/β-catenin pathway involves the bin -
ding of Wnt proteins to LRP5 or 6 and a member of
frizzled (Fz) family of proteins, increasing intra-
cellular β-catenin levels which promote the tran-
scription of target genes inside the nucleus. Its role
in bone biology, RA and OA, has been highlighted.
Wnt/receptor Fz is inhibited by members of the
secreted frizzled-related protein family (sFRP) and
Wnt inhibitory factor (WIF-1). Sclerostin (enco ded
by SOST gene) blocks LRP5 activity6. Inactivating
mutation of Wnt co-receptor LRP5 and the lack of
β-catenin, blocks the expression of transcription
factors that determine osteoblastic phenotype and
the mesenchymal cell achieves another phenotype
(chondrocyte or adipocyte)6,8, which results in re-
duced OPG expression and bone loss.
The Wnt signaling in osteoprogenitors promotes
new bone formation by functioning as a positive
regulator and upregulating OPG and down-regu-
lating RANKL. Kamiya et al7,  found that osteoblasts
respond to BMP signaling to support differentia-
tion of osteoclasts through RANKL/OPG pathway,
possibly by downregulating Opg gene and upre gu -
lating Rankl. It was also showed in mice that BMP
signaling via BMP1A receptor directs osteoblasts to
reduce bone mass by upregulating sclerostin ex-
pression as a Wnt inhibitor, and supporting osteo-
clastogenesis through the RANKL/OPG pathway. 
Dkk-1 is a soluble inhibitor of Wnt pathway and
a negative regulator of osteoblastogenesis in vivo
(in mice)40. Diarra et al41, proposed that Dkk-1 is a
master regulator of joint remodeling, shifting the
balance from bone resorption (increased Dkk-1 ex-
pression) to bone formation (decreased Dkk-1 ex-
pression).  Wnt inhibitors Dkk-1 and 2 can induce
osteoclastogenesis by changing the RANKL/OPG
pathway in vitro42 (Figure 5). 
Wnt system activation seems to be responsible
for syndesmophyts growth in SpA.
New hypothesis
IL-6 is a mechano-sensitive cytocine and probably
a key factor to the biomechanical control of bone
remodeling in OA, possibly decreasing OPG/RAN-
KL ratio43,44.
TGFβ inducible early gene-1 (TIEG) directly
binds to and inhibits OPG promoter activity in os-
teoblasts, explaining the possible inability of TIEG
knockout osteoblasts to support osteoclast diffe -
rentiation45.
Leukotriene B4 is capable of inducing osteoclast
differentiation by a RANKL-dependent mecha-
nism46.
Pigment epithelium-derived factor (PEDF), the
most potent inhibitor of angiogenesis, up-regu-
lates OPG and thus inhibits osteoclast function by
regulating OPG expression47. 
MSCs can differentiate into adipocytes, osteo -
blasts, and other cells. There are a reciprocal rela-
tion between adipogenesis and osteogenesis. Der-
Chih et al48, identified cAMP/PKA signaling, that
silva i. e col.
Fi­gu­re­5.­A model of the relationship between BMPR1A
and canonical Wnt signaling in mouse bone. Wnt inhibitors
Dkk-1 and 2 can induce osteoclastogenesis by changing
the RANKL/OPG pathway in vitro. 
From: Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M,
e tal. BMP signaling negatively regulates bone mass
through sclerostin by inhibiting the canonical Wnt 
pathway. Development 2008;135:3801-3811.
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regulates bone homeostasis, as a via controlling
cyto-differentiation of MSCs (adipocytogenesis,
osteogenesis, osteoclastogenesis) by controlling
the release of leptin and altering RANKL/OPG gene
expression. 
The leucine-rich repeat-containing 17 (LRRc17)
is a member of the LRR superfamily that acts as a
negative regulator of RANKL-induced osteoclast
differentiation (by decreasing NFATc1 expression
depending on phospholipase C signaling), and
thus, is a specific inhibitory molecule for osteo-
clastogenesis. Recombinant LRRc17 did not affect
the differentiation of other myeloid precursors. The
regulation of LRRc17 expression in oteoblasts by
1,25(OH)2D3 suggests that this molecule is pro-
duced by osteoblasts and regulates its interaction
with osteoclasts49.
Emerging treatments
RANKL-SPECIFIC RECOMBINANT FULLY HUMAN MONO-
CLONAL ANTIBODY (DENOSUMAB): clinical trials showed
its effectiveness in suppressing bone resorption,
with an increase in BMD in postmenopausal wo -
men with osteoporotic low BMD50, and have the
potential to prevent progression of erosions in RA
and metastatic bone disease. The recently pub-
lished FREEDOM study51 assessed the effects on
fracture reduction in postmenopausal osteoporo-
sis, and achieved a reduction of vertebral and hip
fractures to 2,3% and 0,7% respectively, compared
to 7,2% and 1,2% in the placebo group. As in the
other trials, adverse events (infections or neo-
plasm) were similar to placebo4,8.
OPG:beside its ability to inhibit osteoclastic ac-
tivity, OPG can promote cell survival by inhibiting
TRAIL-induced apoptosis52. A randomized con-
trolled trial was conducted in postmenopausal
women to determine the effect of a single subcu-
taneous dose of OPG on bone resorption (by uri-
nary N-telopeptide and seric alkaline phospha -
tase). It concluded that OPG acted primarily on os-
teoclasts to decrease bone resorption and that a
single OPG subcutaneous dose (3mg/Kg) was ef-
fective to reduce the bone turnover for a sustained
period52,53. However, OPG has also been reported as
a potential survival factor for several different cell
types, through the TRAIL activity inhibition. Breast
cancer cells produce OPG in order to be protected
from the TRAIL effects in vitro54. Holen et al,
demonstrated that OPG can act as an endocrine
survival factor for breast cancer cells55. This new
unexpected role of OPG discouraged investigators
to further studies of the OPG administration bone
effects. OPG might be a therapeutic option for
bone lysis in metastatic breast cancer and in mul-
tiple myeloma. OPG is a potential marker of
prostate cancer progression or relapse, and a po-
tential marker of bone disease in renal osteodys-
trophy52.
Conclusion
The RANK/RANKL/OPG pathway mediates the ef-
fects of the calciotropic hormones in different tis-
sues and their imbalance contribute to several cli -
ni cal rheumatologic and non-rheumatologic con-
ditions. Multiple molecular discoveries gave rise
to different mechanisms of interaction between
signaling pathways that tried to explain bone for-
mation/resorption. According to this develop-
ment, new emerging treatments have been stu -
died, like denosumab already approved by the
Food and Drug Administration (FDA) and the Eu-
ropean Medicines Agency (EMA) for the treatment
of postmenopausal osteoporosis and the potential
role of OPG as an osteoclastic inhibitor and a cell
survival promoter. 
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